About Us Management

Howard J. Verrico, MD
CEO and Chairman of the Board

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.

Géraldine Deliencourt-Godefroy, PhD
Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.

Christopher Hopton, CGA
Chief Financial Officer

Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 25 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

HajduAttila Hajdu
Chief Business Development Officer

Attila Hajdu is the Chief Business Development Officer for Sirona Biochem. Mr. Hajdu provides leadership and value by strategically identifying and evaluating new growth opportunities consistent with Sirona’s core competencies and strategy. Prior to joining Sirona Biochem, Mr. Hajdu held various senior leadership positions within GlaxoSmithKline and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development. Mr. Hajdu received an MBA from Queen’s University and an MSC in Biochemistry from the University of Western Ontario.

Seltenrich-head shot-smallMichelle Seltenrich
Vice President, Operations

Michelle Seltenrich brings 15 years of experience, with 10 years in publicly traded biotech companies. Her experience ranges from pharmaceutical lab management to corporate development in mergers/acquisitions. Ms. Seltenrich was previously Manager of Business Development at Forbes MediTech and was responsible for international business development, in-licensing and M&A. She worked exclusively with senior management and investment banks in the areas of due diligence and M&A recommendation and played a key role in the successful  acquisition of a U.S. based biotech company. Ms. Seltenrich developed and chaired Forbes’ IP Management Committee, a team dedicated to the creation of an in-house document control center to meet FDA standards.  Ms. Seltenrich holds a BSc from the University of British Columbia and her MBA in Technology Management from Simon Fraser University.





Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.